Industry Insight
Discovery Technology
Analytical Laboratory Technology
Biopharma
Manufacturing
Delivery Systems
Ingredients, Formulation and Finishing
Bioprocessing
View our other publications with free access to extensive archives
  To print this article:
Existing subscribers please log in:
 
  USER NAME  
  PASSWORD  
   Or select

Or become a subscriber
 
 
 

CCMS: A New Era in Toxicoproteomics

Capture Compound Mass Spectrometry (CCMS) represents a powerful platform technology for the generic identification of a drug’s mode of action, as well as the prediction of potential off-targets responsible for adverse side effects.

By Friedrich Kroll, Mirko Glinski, Mathias Dreger, Erik Dulsner and Hubert Koster at caprotec GmbH (July 2009)

Keywords: toxicoproteomics, CCMS, platform technology, side effects, in vitro, compound

    View full article    |    Back to Analytical Laboratory Technology section




Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPTonline © 2004 The Pharmaceutical Technology Journal | Terms and Conditions | info@iptonline.com | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |